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Abstract: Patients with COPD have high risk for osteoporosis and fractures. Hip and 
vertebral fractures might impair mobility, and vertebral fractures further reduce lung function. 
This review discusses the evidence of bone loss due to medical treatment opposed to disease 
severity and risk factors for COPD, and therapeutic options for the prevention and treatment 
of osteoporosis in these patients. A review of the English-language literature was conducted 
using the MEDLINE database until June 2009. Currently used bronchodilators probably lack 
adverse effect on bone. Oral corticosteroids (OCS) increase bone resorption and decrease bone 
formation in a dose response relationship, but the fracture risk is increased more than reflected 
by bone densitometry. Inhaled corticosteroids (ICS) have been associated with both increased 
bone loss and fracture risk. This might be a result of confounding by disease severity, but high 
doses of ICS have similar effects as equipotent doses of OCS. The life-style factors should be 
modified, use of regular OCS avoided and use of ICS restricted to those with evidenced effect 
and probably kept at moderate doses. The health care should actively reveal risk factors, include 
bone densitometry in fracture risk evaluation, and give adequate prevention and treatment for 
osteoporosis.
Keywords: COPD, corticosteroids, bronchodilators, bone mineral density, osteoporosis, 
fractures
Introduction
Chronic obstructive pulmonary disease (COPD) is, and will increasingly be, a major 
cause of morbidity and mortality worldwide.1 COPD develops as a consequence of 
genetic susceptibility, increasing life span, environment and life-style factors. Aging 
of the population, shared risk factors, especially tobacco smoking, systemic effects by 
the disease and side effects of treatment contribute to the fact that COPD patients often 
have many co-morbidities.2–4 among these osteoporosis and increased fracture risk.
Patients with moderate to severe COPD have limitations in physical activity, and 
fractures inevitably could be a heavy additional burden to their dyspnea. Among the 
oldest, the often disabling consequences of hip fractures frequently initiate the patients’ 
need for home care, transfer to nursery homes and shortening of life. Vertebral fractures 
influence the mobility of the patients, are associated with back pain, and may also 
increase dyspnea, as increased thoracic kyphosis and decreased rib mobility add a 
restrictive component to their lung disease,5,6 Hence, effort should be given to secure 
as good “bone health” as possible in this group of patients.
The aims of this paper are to discuss the potential and observed adverse effect on 
bone by the medical treatment given to COPD patients, and also discuss to some extent, International Journal of COPD 2009:4 366
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the contribution by the disease itself, life-style factors and 
co-morbidities. Further, preventive and treatment strategies 
for osteoporosis are discussed.
Methods
A MEDLINE literature search for English language papers 
published until June 2009 was conducted using relevant 
key terms, in addition to examination of reference lists from 
pivotal studies and reviews.
Medical treatment of COPD
According to the Global initiative for chronic Obstructive 
Lung Disease’s guidelines (GOLD), www.goldcopd.com, 
bronchodilator medications are the main symptomatic 
treatment of COPD and these include short and long-acting 
β2-agonists and anticholinergics. They increase exercise 
capacity and health status, whilst long-acting anticholiner-
gics additionally reduce the rate of COPD exacerbations and 
improve the effectiveness of pulmonary rehabilitation. The-
ophylline also is effective in COPD, but due to its potential 
toxicity inhaled bronchodilators are preferred.1
Inhaled corticosteroids (ICS) are recommended for severe 
COPD patients with repeated exacerbations, as they have 
been shown to reduce the frequency of exacerbations and 
thus improve health status. ICS combined with a long-acting 
β2-agonist (LABA) are more effective than the individual 
components.1 A recent network meta-analysis by Puhan and 
coworkers concluded that for mild to moderate COPD, single 
treatment with LABA or long-acting anticholinergics was the 
treatment of choice both for symptom control and exacerba-
tion prevention, but for those with FEV1  40% predicted, 
long-acting anticholinergics was as effective as combination 
treatment in reducing exacerbations.7
Oral corticosteroids (OCS) are recommended for 
7 to 10 days with 30 to 40 mg prednisolone in exacerbations 
in patients with severe COPD, but chronic treatment with 
OCS should be avoided.1
Osteoporosis
Bone
The skeleton is essential for terrestrial animal life, and 
human beings have evolved bone light enough to enable 
rapid mobility and strong enough to avoid disabling fractures 
during reproductive life.8
Bone mass reaches the peak at age 25 to 30 years.9 After 
a plateau phase, bone loss occurs throughout life with an 
age-associated annual bone loss of approximately 0.5% to 
1%, but the rate of loss differs by sex, skeletal sites and age. 
In men, there is a rather constant bone loss from age 25 to 
39 years, this increases mainly at the hips at age 65 years,10 
with further loss of cortical bone above the age of 75 years.11 
In women, bone loss begins at age 40 to 44, and is particularly 
rapid in the total hip at age 50 to 54 with a change of –6.8% 
over 5 years, with another acceleration in loss after age of 
70 years.10,11
Prevalence of osteoporosis
Osteoporosis is the main risk factor for fragility fractures, 
defined as a fracture occurring after a fall from standing 
height or minor trauma. The lifetime risk of any fracture at 
age 50 years is about 50% among women and 20% among 
men.12 Men at age 75 years have equivalent fracture risk as 
women aged 65 years.13
Osteoporosis is defined as a skeletal disorder character-
ized by compromised bone strength predisposing a person 
to an increased risk for fracture. Bone strength primarily 
reflects the integration of bone density and bone quality.14 
An operational definition of osteoporosis, established by The 
World Health Organization (WHO), is based on bone mineral 
density (BMD).15 Bone densitometry results are given as area 
density, but also as T-scores (standard deviations [SD] com-
pared with young adult sex-matched controls) and Z-scores 
(compared with age-and sex matched controls). The WHO 
has defined osteopenia as BMD T-score –1 to –2.5 SD and 
osteoporosis as T-score below –2.5 SD.15
Measures of BMD, bone quality  
and bone metabolism
Dual energy absorptiometry (DXA) at the hip is the best 
predictor of hip fractures and best standardized for the 
diagnosis of osteoporosis. Spine and hip BMD have similar 
value for predicting spine fractures,16 but spondylarthrosis 
and minerals in the aorta might give artificially high values 
of BMD in the anterior-posterior directed measurements after 
the age of 60 to 65.17
BMD at these sites are widely used in clinical practice 
to identify those at increased risk for fracture. However, 
a majority of fragility fractures occurs in women not being 
defined as osteoporotic.18 The prediction of fractures in 
both genders improves if baseline BMD is replaced with 
change in BMD between measurements in the models.19 
Most clinicians, however, have to rely on one measurement 
estimating the patients fracture risk. Compared to other risk 
factors, BMD is at least as good in prediction of fracture as 
blood pressure measurements to predict stroke and level of 
cholesterol to predict cardiac infarction.20International Journal of COPD 2009:4 367
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T-scores between different sites should not be compared, 
due to site differences regarding accuracy errors, variance 
in the population and algorithms for edge detections.21 In a 
study of the same population of a DTX-base, the prevalence 
of osteoporosis in women aged 50 years or more, ranged 
from 11% at the hip, 24% at the spine, to 52% at the distal 
radius.22
Mainly for research purposes, methods like Single X-ray 
Absorptiometry (SXA), Quantitative Ultrasound (QUS) 
and Quantitative Computed Tomography (QCT) have been 
used. Although measurement at a specific site is the best 
predictor of fracture at that site, forearm SXA is as good 
as lumbar BMD for prediction of hip fracture,23,24 other 
non-spine fractures25 and fragility fractures in general.26 
Correspondingly, quantitative ultrasound (QUS) of calcaneus 
has been used to estimate regional BMD-levels, evaluate 
bone quality27 and predict fracture risk,28,29 but this method 
has poor sensitivity for detecting osteoporosis defined as 
T-score  –2.5 SD.30
Markers of bone turnover, as alkaline phosphatase, 
hydroxyproline, osteocalcin, pro-collagen peptides and 
pyridinium crosslinks, can enhance the predictive value of 
BMD.20 However, due to large biological variability, they 
are of uncertain clinical relevance and have not been shown 
to predict the risk of fracture31,32 or to correlate with changes 
in BMD.33 They might, however, reflect changes related to 
antiresorptive therapy more rapidly than changes in BMD.34 
In general, corticosteroid (CS) administration is followed 
by a reduction in bone formation markers, especially serum 
osteocalcin levels,35–37 and a trend to an increase or no change 
in bone resorption markers.38
risk factors for osteoporosis  
and fracture in COPD
High age and female sex are important risk factors 
for osteoporosis, with postmenopausal loss of ovarian 
hormones being the single most important factor. The 
prevalence of osteoporosis and incidence of fragility frac-
tures differ substantially between populations, with highest 
figures in post-menopausal women of Northern European 
descent, especially those living in Scandinavia.12,39–41 Both 
parental osteoporosis and fragility fractures, as well as 
previous fracture in the patient, are risk factors for further 
fracture.42
Patients with COPD are at high risk for osteoporosis and 
fractures because of lifestyle factors, systemic effects of the 
disease, treatment and comorbidities (Figure 1). Smoking is 
associated with low BMD in a dose-response relationship, 
Low BMD
I
n
c
r
e
a
s
e
d
 
f
r
a
c
t
u
r
e
 
r
i
s
k
Genetics
Mal-
nutrition
Low Ca
Low vitamin D 
Low 
socio-
economic
status Smoking
Inflammation
Il-6, Il-1β,TNF-α
COPD
Inactivity
Cortico-
steroids
Comorbidities
Muscle wasting
Weight
loss
Sex
Ethnicity
Falls
Neuro-
muscular 
diseases
Previous 
fractures
Family 
fractures
B
o
n
e
 
m
i
n
e
r
a
l
 
d
e
n
s
i
t
y
Age
Figure 1 The development of bone mineral density (BMD) throughout life, factors of importance for level of BMD (genetics, sex), COPD-related factors lowering (BMD), and 
important factors influencing fracture risk in addition to level of BMD.
Abbreviations: IL, interleukin; TNF-α, tumor necrosis factor alpha.International Journal of COPD 2009:4 368
Langhammer et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
not only in current smokers, but even ex-smokers.43,44 Female 
lungs seem to be more susceptible to harmful effects of 
tobacco smoking than male lungs.45,46 Increased prevalence 
of smoke related lung diseases in women and increasing pro-
portion of women among smokers, might affect bone more 
negatively in women than men, through combined effects of 
COPD and smoking.
Furthermore, inactivity is an important risk factor for 
osteoporosis and fractures, partly due to increased risk for 
falling. A physically active life has been found to nearly halve 
the incidence of hip fractures in the older population,47 and 
appendicular lean mass accounts for most of the explained 
variance among factors being positively associated with 
BMD.41
COPD patients, as well as patients with other chronic 
diseases, often have deficient calcium (Ca) and vitamin D 
nutritional status,48,49 and the latter is frequently accentuated 
because of little exposure to sunlight. Weight loss is also 
associated with decreased BMD50–52 and a recent review 
reported BMD to be 3% to 7% higher for every 10 kg 
increase in weight.43 Correspondingly, a recent study found 
that 5% weight loss was associated with a 33% increased 
risk of forearm fractures.53
In the recent years, a detrimental effect on bone also 
caused by COPD itself has been suggested.3,54 Among many 
possible explanations, most current evidence indicates that 
this is a result of mediators, cytokines (interleukin [Il]-6, 
Il-1β and TNF-α) or activated inflammatory cells reaching 
the systemic circulation from inflammation in the lungs.3,4 
The extent of this contribution is unclear, but the fact that 
patients on OCS have higher risk of fractures compared to 
untreated patients with similar underlying inflammatory 
diseases55 indicates that this is not one of the main causes of 
the influence on bone.
Medicine-induced osteoporosis in COPD
Many studies have addressed this subject, but the main 
problem or limitation of many of these studies are the power 
to reveal any effect, and, in case of effect, to differentiate 
between possible effects by medication, disease severity 
and factors mentioned above. There have been a few large, 
randomized, double-blind, clinical trials (RCT), many obser-
vational case-control and cohort studies, in addition to many 
meta-analyses. Some larger and important studies are based 
on registers as the UK General Practice Research Database 
(GPRD) (190,000 to 240,000 cases using CS).56,57 and Danish 
data based on the National Hospital Discharge Register and 
others (125,000 fracture cases).58
How can adverse effects on bone 
be measured?
Outcomes such as fractures, or surrogate measures of fracture 
risk, as BMD and biochemical markers for bone turnover, 
might be relevant for studies on adverse effects on bone. RCT 
including fractures as primary outcome would give the best 
evidence of such an effect. However, even as lifetime fracture 
risk is high, only a small number of subjects at risk actually 
sustain a fracture during few years observation time. For 
example, in any year, fractures occur in 1 to 2 per 100 women 
aged 65 years, 6 to 10 per 100 women aged 75 years, and 
only 1 to 2 per 2,000 of the 15% of women 60 years of 
age with osteoporosis.59 Even for BMD, there are problems 
with the power of studies. Wisniewski et al calculated that a 
prospective study comparing a dose of 1 mg beclomethasone 
dipropionate (BDP) equivalents with placebo, would require 
2,500 individuals in each limb for 95% power to detect the 
difference of 0.1 SD in BMD found in their cross-sectional 
study.60
Airway obstruction, COPD and bone
Airflow obstruction is associated with increased risk of osteo-
porosis compared with normal lung function.61,62 COPD is an 
independent predictor of BMD reduction63–65 and vertebral 
fracture risk.66 Studies have shown more than two-fold preva-
lence of osteoporosis in CS-naïve COPD patients, compared 
both with healthy controls67 and asthma patients.68 Increasing 
disease severity increases the risk for osteoporosis,29,61,69 and 
in severe COPD osteoporosis and osteopenia have been found 
in as many as 66% and 31%, respectively.70
Correspondingly, the fracture risk is positively associ-
ated with COPD severity.71 In mild COPD the fracture risk 
is similar to what was found in the European Vertebral 
Osteoporosis Study (EVOS),72 with a prevalence of vertebral 
deformity of 12% in both genders aged 50 to 79 years,73 
but more COPD patients than healthy, had at least 1 severe 
vertebral fracture (OR = 3.75).6 Nuti et al reported at least 1 
vertebral fractures in about 40% of COPD patients, with a 
strong association between disease severity and fractures, 
especially in men,71 and in a recent Norwegian study, the 
number of vertebral deformities was almost twice as high 
in GOLD stage III compared to II in women.74 In the large 
Danish register study, comparing subjects with and without 
COPD, COPD adjusted for use of CS was associated with 
increased risk for hip and vertebral fracture (relative risk [RR] 
1.63 and 1.23), but not for forearm fractures. Comparing 
those with and without asthma, revealed an asthma-related 
increased risk for only hip fracture (RR 1.32).58International Journal of COPD 2009:4 369
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Vertebral compression fractures often are asymptomatic, 
and among severe COPD patients, not previously diagnosed 
compression fractures were found in 24%.75 A prospective 
study revealed that compared to subjects without COPD, 
incident COPD patients had increased risk for osteoporosis 
and fracture (RR 3.1 and 1.6, respectively) within the first 
year after diagnosis.2
Treatment of COPD and effect 
on bone
Oral glucocorticoids
A GPRD study documented that women aged 85 years 
using 7.5 mg prednisolone daily had an excess in number 
of hip fracture cases of 1.4 cases per 100 patients per year 
compared to non-users, and as many as 47% and 72% of all 
hip and vertebral fractures, respectively, could be attributed to 
OCS.76 Walsh et al found that patients on OCS for 6 months 
compared to controls had increased risk of osteoporotic 
fractures of the vertebrae (OR 10), hip (OR 6), and ribs or 
sternum (OR 3.2).77
In a comprehensive meta-analysis van Staa et al found 
strong correlations between cumulative dose and bone loss 
and between daily dose (5 mg prednisolone) and risk of 
fracture. The fracture risk increased within 3 to 6 months 
after the start of OCS, and decreased after stopping therapy. 
The increased risk remained independent of underlying 
disease, age and gender.78 Later, van Staa79 reviewed several 
large population based studies on fracture risk in CS users, 
and found consistent increased fracture risk in CS users in 
the hip (RR 1.61 to 2.01) and spine (RR 2.60 to 4.16). Only 
one study from the GPRD showed a minor increased risk 
for forearm fractures compared to controls (RR 1.09).57 In a 
study by Angeli et al including 551 post-menopausal women 
given CS for different diseases, the adjusted prevalence of 
asymptomatic vertebral fractures was 38% for asthma/COPD. 
No significant association, however, was found between 
fractures and CS cumulative dose or duration of therapy.80
These studies confirm that the vertebral bodies are 
affected earlier and more severely than cortical bone of the 
long bones (radius, humerus) during OCS treatment.81 Differ-
ent patterns of loss have also been demonstrated within the 
lumbar spine with greater damage to the trabecular bone than 
the cortical bone of the spinosi and apophyseal area.82
Dose response relationship
There have been discussions on a threshold dose above which 
oral CS cause bone loss. The two large register-based studies 
both found increased risk for hip and vertebral fractures in a 
dose response relationship above daily doses as low as 2.5 mg 
prednisone equivalents,57,58 and similar results have later been 
demonstrated by de Vries et al56 (Table 1). In line with this, 
Li et al found that COPD patients with a fracture history, 
reported treatment with higher doses of prednisone compared 
to those without fractures.70
However, opposed to this, recent analyses of the Danish 
register83 and the Dutch PHARMO-RLS database84 did not 
find any increase in overall fracture risk for prednisolone 
doses 7.5 mg per day. This could be a result of less residual 
confounding due to adjustments for proxies for disease 
severity and other risk factors for fractures. A limitation of 
register-based studies, is lack of individual life style data, but 
inclusion of such data rather should weaken the association 
between CS use and fracture.
Increased fracture risk by duration of OCS use has been 
found in studies on patients with rheumatoid arthritis and 
lupus,85–87 and both Walsh77 and de Vries56 with coworkers 
have reported a substantial increased risk for fractures with 
increasing cumulative dose of CS. Walsh found that the 
highest compared to lowest cumulative quartile (median 
prednisolone dose 61 g versus 5 g) had an increased risk 
ranging from 2 for all fractures to 9 for vertebral fractures.77 
Table 1 Adjusted odds ratio for fracture risk at different sites by daily dose of prednisolone in UK General Practice research Database 
(GPrD) and Danish large register studies
Prednisolone 
daily dose
Danish register study   Vestergaard et al58 GPRD study Van Staa57 GPRD study de Vries et al56
Forearm Hip Spine Hip Spine Hip/femur Spine
2.5 mg 0.99 (0.89–1.09) 0.97 (0.87–1.08) 1.16 (0.95–1.41) 0.99 (0.82–1.20) 1.55 (1.20–2.01)
1.40 (1.24–1.57) 2.89 (2.47–3.39)
2.5–7.49 mg 1.14 (0.98–1.33) 1.27 (1.11–1.44) 1.54 (1.18–1.99) 1.77 (1.55–2.02) 2.59 (2.16–3.10)
7.5 mg 1.19 (0.99–1.43) 1.45 (1.25–1.69) 2.08 (1.54–2.79) 2.27 (1.94–2.66) 5.18 (4.25–6.31) 2.17 (1.87–2.51) 4.00 (3.29–4.86)
Notes: The Danish study comprised 124,655 subjects having sustained a fracture during the year 2000 compared to matched controls.58   The GPrD study by van Staa comprised 
244,235 oral corticosteroid (OCS) users compared to matched controls aged 18 years. respiratory disease accounted for 40% of treatment indications.57 The GPrD-study 
by de vries comprised 191,752 subjects aged 40 years who received OCS compared to past users of CS.56International Journal of COPD 2009:4 370
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Results from two RCTs, however, indicated that not the 
cumulative, but the daily CS dose was a strong predictor for 
vertebral fracture, with 60% increase in risk for each 10 mg 
increase in prednisolone dose.88 Based on an administrative 
US database, Steinbuch et al reported dose response relation-
ship for both duration and dose of OCS. Long and continuous 
use of CS resulted in a significant 5-fold increased risk of hip 
and 6 fold increased risk of vertebral fractures. Adding high 
doses of prednisolone to this, the RR increased to 7-fold for 
hip and 17-fold for vertebral fractures.89
CS related bone loss is most rapid during the first 
6 months of OCS treatment (on average 5%), after which 
there seems to be a slower but steady loss of bone (1% to 
2% per year).90,91
An increased risk for fractures has been shown for doses 
above 5 mg/day within 3 to 6 months after initiation of OCS 
therapy,78,89 and for doses of 10 mg prednisolone for less 
than 60 days with an increasing trend by time.83 Vestergaard 
and coworkers also found an effect of lower doses within 
60 days, but this effect did not last beyond 2 months, and 
was probably an effect of confounding by indication. 
Correspondingly, van Staa found increased fracture risk even 
before OCS was initiated.57
Avoidance of continuous use has been believed to reduce 
adverse effects on bone.92 Alternate, in stead of daily use of 
OCS has not been found to reduce bone loss in adults.93,94 
However, long-time sporadic use has been reported to be 
associated with a 2-fold increased fracture risk, compared to a 
6-fold increased fracture risk in those with continuous use of 
OCS 89. In a GPRD study, patients with previous cumulative 
dose CS  1 g with intermittent high-dose CS (daily 
dose 15 mg) only had a small increased risk, whilst those 
with a daily dose 30 mg and cumulative exposure 5 g 
had a relative risk of hip/femur and vertebral fracture of 
3.13 and 14.42, respectively.56
Treatment of exacerbations is an important exposure 
for OCS in COPD patients. Dubois et al showed that OCS 
courses were associated with more harmful effects against 
bone compared to continuous OCS treatment regimens 
(10 mg prednisolone/day).95 The study indicated alarming 
bone loss of a cumulative dose above 1 g of prednisolone 
equal to 2 to 3 OCS courses. Corresponding effect on lumbar 
BMD has been reported in asthma patients receiving more 
than 2.5 courses of OCS compared to fewer.96
reversible effect
Regaining of BMD to normal levels was found in the 1990s 
in patients cured for Cushing disease97 and patients having 
stopped OCS therapy.87,98 Newer register studies showed 
that the increased risk of fracture in OCS-users mostly 
disappeared within one year after stopping therapy, most 
pronounced for vertebral fractures, but even the risk for 
hip fractures was reduced towards baseline levels.57,58,83 
There is a rapid decrease in fracture risk beginning already 
three months after stopping CS treatment,56 but the time for 
fracture risk to return to normal, depend on the cumulative 
dose used, from 6 months after cumulative dose of less than 
1 g prednisolone to at least 15 months at higher cumulative 
dose and daily dose above 15 mg.56 However, at cumulative 
doses 10 g there is both a thinning and perforation of the 
trabeculae of such an extent that bone recovery is precluded 
after withdrawal of CS.99
OCS and BMD
Due to disruption of collagen structure and bone architec-
ture, rather than demineralization by CS treatment,100,101 the 
increased fracture risk in OCS users seems to be mostly 
independent of BMD. This explains why adjustments for 
BMD have not changed substantially the relative fracture 
rate in OCS,102 and why CS users compared to non-users 
have higher risk for vertebral fractures at the same levels 
of BMD.88
However, bone loss due to OCS can be measured by 
BMD. This was first found after short time use in patients 
with rheumatoid arthritis and chronic fatigue syndrome;98,103 
a mean daily dose of 7.5 mg prednisolone for 20 weeks led to 
9% increased loss in trabecular bone compared to placebo.98 
Corresponding effects of OCS on BMD are found in COPD 
patients.
ICS and bone
Medication for inhalation was developed in order to ensure 
high deposition in the airways with lowest possible systemic 
side effects. Even though the gastrointestinal absorption of 
ICS like budesonide (BUD) and fluticasone (FLU) is very 
low compared to BDP and triamcinolone (TCA),104 the active 
medication deposited in the airway, will reach the systemic 
circulation. Adverse effects on bone could be possible, and 
reviewers have found reason to concern about this.105,106
ICS and fractures
randomized controlled trials (rCT)
As part of a systematic review and meta-analysis of RCT, 
Drummond et al included three larger studies on ICS with 
fractures as secondary outcome.107 The studies compared 
combined salmeterol (SAL)/fluticasone (FLU) with each International Journal of COPD 2009:4 371
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components alone and placebo for a period of 3 years in 
6,112 COPD patients,36 FLU with placebo in 751 patients 
with moderate to severe COPD,108 and BUD with placebo in 
1,277 smokers with mild COPD for 3 years.73 Despite use of 
rather high doses (FLU 500 µg twice daily and BUD 400 µg 
twice daily), no difference in fracture risk was found between 
the treatment groups. A Cochrane review of seven RCT found 
no effects of 2 to 3 years use of conventional doses of ICS 
on BMD or fracture risk, but very high doses were associ-
ated with increase in markers of bone turnover.31 Altogether 
the studies included cases with mild to severe COPD, doses 
considered as moderate to high, but the follow-up time was 
short compared to what is the case for most COPD patients.
Observational studies
Knowledge on potential effects of ICS on bone could be 
derived from studies including asthma patients, as these lack 
many of the negative life-style factors characteristic of COPD 
patients. Lipworth et al in 2002 reviewed available literature 
on ICS and systemic adverse effects published from 1966 
through 1998, and found that all ICS, but especially FLU 
(at doses above 800 µg), exhibited dose-related adrenal sup-
pression, a risk factor for bone loss. Data on bone turnover, 
however, were not included in these studies.109
In 2003 Richy et al reviewed all controlled trials having 
data on ICS, and BMD/markers/fractures in asthma, COPD 
and healthy persons.110 Data from the included studies 
showed that all considered ICS, compared with placebo or 
controls, appeared to affect bone markers or lumbar BMD 
in asthma, COPD or in healthy adults, but the study lacked 
power to investigate fracture risk. TCA led to the most 
deleterious effects on bone, followed by BDP and BUD. 
There was a dose response relationship, both regarding 
daily dose and duration of ICS use, and bone loss. Assum-
ing a linear bone loss in CS-induced osteoporosis, use of 
TCA 1 mg/day during 20 years would lead to an estimated 
6.7% decrease in BMD compared with unexposed asthma 
or COPD controls, whereas corresponding figure for BUD 
would be 2.4%. However, as the authors discussed, there 
might be not-linear time-effect model due to compensatory 
mechanisms in patients exposed to ICS on a long-term basis. 
Furthermore, two of the studies73,111 included specifically 
smokers, who where older than in the other studies. Exclud-
ing these, rendered the results non-significant, suggesting that 
an effect of aging, smoking and higher cumulative dose of 
ICS might have influenced the results.
Based on the Danish register, Vestergaard et al found 
a limited increase in the risk of any fracture, but not hip, 
spine or forearm fractures, in ICS-users of more than 7.5 mg 
prednisolone equivalents per day (equivalent to 1875 µg of 
BUD per day).58 Van Staa et al based on GPRD data, four 
years earlier, had reported increased risk for fracture at all 
these sites, and even in a dose-response relationship effect 
by ICS. However, they did neither find differences in fracture 
risk between the ICS and bronchodilator groups compared 
with non-users, nor between users of different ICS (BUD, 
FLU and BDP).112 Restricting a study to elderly women in the 
same database, Hubbard et al, found ICS-use to be associated 
with increased fracture risk (OR 1.19 adjusted for OCS) and 
in a dose response relationship.113 Including disease severity 
indicators as confounders in a study from the same database, 
de Vries et al found that the crude two-fold fracture risk at 
the hip in patients on high dose ICS (1.6 mg) was reduced 
to similar risk as non-users of ICS,66 and later they found 
similar result in a Dutch study.84
However, even recent studies have reported a small 
increase in fracture risk by ICS, but mainly with use of 
higher doses.71,114,115
CS have less influence on appendicular bone than hip and 
spine. Even so, in a cross-sectional population-based study 
in Norway, current users of only ICS had 2% lower forearm 
BMD compared to ICS-naïve individuals, and additional 
use of OCS was associated with 8% lower BMD.116 Similar 
results were found during a follow-up study for 5 years,117 
but despite the possibility to adjust for both diseases severity, 
other risk factors and individual life style factors, lack of any 
dose response relationship between ICS-use and BMD, could 
indicate confounding by disease severity.
The studies do not fully preclude adverse effects of at least 
high dose ICS on bone, but what is the clinical relevance of 
such an effect? Weatherall et al addressed this in a recent 
systematic review and meta-analysis of 5 case-control stud-
ies of ICS use.118 The random-effects odds ratio of relative 
risk for a non-vertebral fracture was 1.12 (95% confidence 
interval 1.00 to 1.26) per 1.0 mg increase in the daily dose 
of BDP or equivalent. This risk was considerably less than 
other common risk factors for fracture in the older adult, with 
figures of: 1 or more falls 4.7, use of antipsychotic medica-
tion 2.8, body mass index 18.5 kg/m2 2.4, cerebrovascular 
disease 1.9, use of hypnotic medication 1.7, and being a 
current smoker 1.5.118
what dose level of ICS is used in COPD?
Mild asthma is very responsive to CS, and most of the 
therapeutic effect of ICS is obtained at doses around 400 to 
500 µg of BDP equivalents, with the mean dose achieving International Journal of COPD 2009:4 372
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the maximum benefit being around 1,000 µg/day.119,120 
CS suppress the multiple inflammatory genes that are 
activated through recruitment of the enzyme histone 
deacetylase 2 (HDAC2). Smoking, however, contributes to 
steroid resistance121 through negative effect on HDAC2.122 
Hence, for optimal CS response, COPD patients and smoking 
asthma patients need higher CS doses compared with non-
smokers. As the introduction of ICS combined with LABA 
in asthma patients has led to asthma control at lower ICS 
doses,123 the concern for negative effects on bone among these 
patients are minimized compared to smokers with asthma or 
COPD. Even though significant differences between single 
ICS and combination therapy on BMD and bone metabolism 
markers were not found, a study indicated more favorable 
pattern for the combination therapy.124
RCTs on the effect of ICS on different outcomes in 
COPD patients have mostly used higher doses of ICS than is 
generally used in asthma patients. Daily doses of FLU have 
been 500 µg twice daily,36,108,125–128 BUD 320 to 400 µg twice 
daily73,129–131 and TCA 1,200 µg/day.111 Recently, however, 
Ferguson et al published a RCT reporting a similar reduction 
in annual rate of exacerbation by FLU/SAL 250/50 µg/mg 
twice daily (30% compared with SAL) as reported in previous 
studies of double ICS dose.132 Two other studies of shorter 
duration (24 weeks) showed that FLU/SAL 250/50 bid 
improved lung function and reduced severity of dyspnea 
compared with individual components and placebo, but these 
had not power to study exacerbations.133,134 Further studies on 
defining the lowest dose needed to reach the desirable effects 
of ICS are therefore warranted. Today there is a discrepancy 
between the size of doses used in the majority of studies and 
doses prescribed in the clinic. In the US, higher doses than 
FLU/SAL 250/50 and BUD/FOR 320/9 µg/mg twice daily 
are currently not approved for use in COPD.
For CS exposure during exacerbations, Stallberg et al in 
a RCT found no difference between 2 weeks of high-dose 
BUD/FOR combination and prednisolone 30 mg.135 Even if 
all patients were given one dose of prednisolone 30 to 50 mg 
before randomization, the total CS exposure in those getting 
ICS would be about one-third of those receiving OCS.
Bone turnover and influence 
of inflammation
In all individuals there is a continuous bone remodeling, 
and in adults about 25% of trabecular and 3% of cor-
tical bone are replaced each year.136 Central cells in 
this balance are osteoclasts, which resorb bone, and 
osteoblasts, which replace lost bone with new matrix, which 
subsequently mineralizes. Osteocytes and their canicular 
network serve as mechanosensors, and play a role in the 
repair of bone microdamage.137 There is a close interaction 
between osteoblasts and osteoclasts, mainly mediated by 
receptor activator of NF-κB ligand (RANKL) and osteo-
protegerin (OPG). RANKL is expressed on the surface 
of osteoblasts, and its expression increases in response to 
different pro-resorptive signals such as proinflammatory 
cytokines, CS, estrogen deficiency and excess of parathyroid 
hormone.138 RANKL is the critical stimulator of the differen-
tiation and activity of ostoclasts leading to bone resorption. 
OPG is a decoy receptor that is secreted by osteoblasts and 
reduces bone resorption by binding to RANKL.139,140
The influence of inflammatory diseases on bone is thor-
oughly discussed in a recent review by Hardy and Cooper.140 
Shortly, inflammatory cells also express or secrete RANKL, 
or produce cytokines (TNF-α and interleukins) promot-
ing bone resorption independent of osteoblasts.141 Why 
increased bone resorption is not followed by bone formation 
is unclear, but at least TNF-α inhibit the differentiation of 
osteoblasts.142
Interestingly, inflammation modifies the action of the 
enzymes, 11β-hydroxysteroid dehydrogenases (11β-HSDs) 
responsible for the intracellular CS metabolism. One of these 
converts inactive CS such as cortisone and prednisone to their 
active counterparts cortisol and prednisolone. Exposure to 
proinflammatory cytokines increases the levels of autocrine 
generated cortisol in the osteoblasts, leading to decreased 
bone formation through direct effect on osteoblasts, as well as 
increased osteoclast activity due to upregulation of RANKL 
and downregulation of OPG.139,143 The 11β-HSDs might con-
tribute to the individual heterogeneity in the response to CS 
therapy. A common polymorphism in the efflux transporter 
P-glycoprotein which is associated with CS sensitivity might 
also confer susceptibility to CS-induced osteoporosis.144
The pathogenesis of CS-induced 
osteoporosis
Figure 2 shows the bone cells and mechanisms being involved 
in CS-induced bone loss. The loss occurs in two phases, 
a rapid early phase, probably due to excessive bone resorp-
tion, and a slower, progressive phase due to impaired bone 
formation.145,146 In the first phase CS increase the expression 
of RANKL and macrophage colony stimulating factor, while 
decreasing the expression of OPG in stromal and osteoblastic 
cells, thereby favoring osteoclast differentiation and bone 
resorption.139 Furthermore, CS decrease the apoptosis of 
mature osteoclasts leading to a prolonged bone resorption.147 International Journal of COPD 2009:4 373
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The excess resorption, however, falls with long-term CS, 
probably due to inhibition of differentiation of osteoclast 
precursors.147
In the second phase, inhibition of proliferation, differen-
tiation as well as maturation of osteoblasts, lead to impair-
ment of bone formation.148,149
CS also exert negative effects on osteocytes by disturbing 
their mechanosensor function and inducing apoptosis.150 
This reduces the strength of bone, independently of changes 
in bone remodeling and architecture,151 and might partly 
explain why patients treated with CS experience fractures 
at a higher BMD level than non-CS users. Additionally, 
CS have an indirect, negative effect on bone formation 
by reducing the expression of insulin like growth factor 
(IGF)1.145 Low levels of gonadal steroids increase bone 
resorption.152 However, even though CS decrease the level 
of these hormones, the adverse effects are still observed in 
patients with maintained menstrual cycle activity implying 
that the adverse effects of CS are largely independent of 
hypogonadism.153
Secondary hyper-parathyroid state, due to the effects of CS 
as inhibitors of calcium absorption from the gastrointestinal 
tract and calcium reabsorption in the renal tubuli, has been 
postulated, but studies have not reported association between 
CS and increased parathyroid hormone.145
Other pathophysiological mechanisms are discussed, 
among these, redirection of differentiation of bone marrow 
stromal cells from cells of the osteoblastic lineage to the 
adipocyte lineage,145 and inhibition of osteoblast differen-
tiation by opposing Wnt-β-catenin signaling.154 The relative 
importance of the various components is not yet known.
CS initially mainly affect trabecular bone due to higher 
metabolic activity, but with prolonged use cortical bone 
is also affected.146 Muscle weakness and atrophy is also a 
consequence of OCS treatment. The changes particularly 
involve the pelvic girdle musculature, with less involvement 
of the shoulder girdle and distal musculature. It generally 
occurs within weeks to months after initiation of OCS. 
In stable patients with COPD, a 2-week course of 30 mg 
prednisolone was not associated with muscle weakness.155
Osteoporosis and fractures associated 
with other medication
Bronchodilators
Overstimulation of the adrenergic system has been 
associated with a low BMD or increased bone fragility,156 
Glucocorticoids
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Figure 2 Diagram showing the direct and indirect effects of glucocorticoids on bone leading to glucocorticoid-induced osteoporosis and fractures. reproduced with 
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and according to experimental studies, activation of 
the β2-receptors on osteoblasts leads to production of 
RANKL resulting in increased osteoclastogenesis and 
reduced BMD.157 Bonnet et al showed that the β2-agonists 
salbutamol and clenbuterol reduced bone mineral content 
and increased the level of bone resorption markers. Opposed 
to clenbuterol, however, salbutamol did not seem to have 
any effect on bone microarchitecture or anabolic effect on 
muscles. Corresponding to these results, a meta-analysis of 
7 studies assessing fracture risk in patients using β-blockers 
concluded that their use was associated with a 28% reduc-
tion in hip fracture risk and a 14% reduction in the risk for 
any fracture.158
Use of convenient doses of β2-agonists probably does 
not affect bone. In 2 large case-control studies increased 
risk of fractures associated with β2-agonist treatment was 
found.159,160 Adjustments for use of OCS and disease severity, 
substantially reduced the excess risk found in β2-agonist 
users, and causal effect of the latter seems unlikely as there 
was no dose dependent relation between use of inhaled 
short-acting β2-agonists and fractures, in as much oral 
β2-agonists were associated with an increase in fracture risk 
at low, but not higher doses.160
A study in rats indicated that theophylline treatment 
promoted skeletal calcium loss,161 and some effect on bone 
turnover markers were reported in a study including patients 
with mild asthma on theophylline treatment.162 However, no 
increased fracture risk by theophylline was found in a study 
by Vestergaard et al,160 and for anticholinergics, de Vries 
et al found similar risk of hip/femur fracture between users 
of β2-agonists, ICS and anticholinergics,159 indicating these 
effects to be caused by underlying disease instead of medica-
tions. Anticholinergics and theophylline might have benefi-
cial effects on systemic inflammation and comorbidities of 
COPD, but this is not proven yet.4 Interestingly, low-dose 
theophylline might also reverse CS resistance in COPD.
risk estimation
Prior presence of other important risk factors enhances the 
adverse effects on bone by life style, COPD itself and treatment, 
and bone densitometry should be considered (Table 2). For 
patients having lost height the possibility of undiagnosed 
vertebral compression fractures should be considered.
Thresholds for treatment of osteoporosis previously have 
been at fixed T-scores given by bone densitometry. Opposed to 
postmenopausal osteoporosis with a recommended threshold 
at T-score –2.5 SD for initiating of treatment, the threshold 
in patients on CS treatment should be higher due to the 
adverse effect on bone not reflected by bone densitometry. 
The American College of Rheumatology has set cut 
off at –1 compared to –1.5 SD in the UK guidelines.163 
This is supported by current evidence of CS effect on 
bone, and encourages more focus on estimation of absolute 
long-term fracture probability.
Many osteoporosis risk-assessment tools have been 
developed,164 and WHI Hip Fracture Risk Calculator (www.
hipcalculator.fhcrc.org) and the FRAX tool (www.shef.
ac.uk/FRAX), for example, could be useful supplements 
to BMD assessments.164,165 However, the tools are based on 
cohort studies, and the data might not be representative for 
all populations. Further, there is limited increase in risk score 
compared to use of BMD alone. For example, at age 50 the 
gradient of hip fracture risk per SD change in risk score was 
2.0, 3.68 and 4.23 with use of clinical factors, BMD and 
both, respectively.166
recommendations for treatment 
of COPD patients
Health care professionals ought to be well aware of adverse 
effect on bone from CS therapy, but risk evaluation is 
performed to a limited extent. In a US study in 2002 of 
osteoporosis intervention in patients on CS treatment, 
bone densitometry was performed in 9% of men and 27% 
of women exposed to OCS and in 4% of men and 23% of 
women exposed to ICS.168
One important aspect of COPD treatment should be to 
avoid bone loss and fragility fractures. This involves change 
in life style, treatment to allow for increased physical activity, 
keep CS exposure as low as possible, Calcium and vitamin D 
and anti-resorptive therapy (Table 3). An important challenge 
Table 2  Dual  energy  absorptiometry  measurements  – 
recommendations
•  Generally
    Sites: hip and lumbar spine
   women 65 years and men 70 years164
     Younger postmenopausal women and men aged 50 to 69 years 
in case of one major or two minor risk factors for osteoporosis164
•  Ideally, all patients starting with OCS, but at least:
    Start of OCS with daily dose 5 mg for 3 months
    Need of 1 OCS course yearly167
•  Measurement interval
    5 years if no risk factors or CS therapy10
    2 years or more to follow loss or treatment effect
    1 year if use of OCS without anti-resorptive treatment
Abbreviations: CS, corticosteroids; OCS, oral corticosteroids.International Journal of COPD 2009:4 375
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is to succeed in communication with all COPD patients. 
Especially, lower socioeconomic classes have high prevalence 
of COPD, but also less adherence to behavior advice.
Calcium and vitamin D supplementation reduce fracture 
risk,171 and early start reduced fracture risk by 12% in one 
study.172 Interestingly, a dose-dependent association between 
vitamin D levels and pulmonary function has been found, and 
vitamin D supplement might extend beyond the protective 
effect on bone, and influence the inflammation in the lungs 
and interfere with co-morbidities of COPD.49
Sex hormone treatment also reduces fracture risk.171 
Estrogen preserves bone in post-menopausal women 
independently of CS use,173 but its use is currently limited 
due to concern for side effects like cardiovascular disease 
and breast cancer. Such treatment, however, should be con-
sidered in hypogonadal premenopausal women exposed to 
CS, because of limited experience with bisphosphonates 
beyond 10 to 12 years.164,174
Anti-resorptive therapy should be considered early 
during OCS treatment, as increased bone loss starts 
immediately after the beginning of treatment in a daily 
dose relationship.175 Bisphosphonates have been reported 
to be the most effective of evaluated agents for managing 
CS-induced osteoporosis, and this effect is enhanced further 
with concomitant use of vitamin D and calcium.176 There 
is strong evidence of reduced fracture risk for most of the 
bisphosphonates, including the intra-venous alternative 
zoledronic acid.171 The main effect of bisphosphonates is 
the inhibition of bone resorption, but they have also been 
shown to prevent osteoblast and osteocyte apoptosis,177 and 
could thereby preserve the integrity of the osteocyte network 
and the osteoblast lifetime.
The American College of Rheumatology recommends 
bisphosphonates in all men and postmenopausal women 
in whom long-term (3 months) CS treatment with daily 
dose 5 mg is initiated, and if T-scores at the spine or hip 
are below –1 SD independent of OCS dose.174 The UK guide-
lines suggest this treatment in patients with high risk for 
osteoporosis; users of 7.5 mg OCS, previous experience 
of a fragility fracture or other risk factors for osteoporo-
sis. Among patients with low risk of osteoporosis, anti-
resorptive treatment should be considered if T-score  –1.5 
SD or decline in vertebral BMD  4% after 1 year of CS 
treatment,163 Vestergaard et al recommended fracture preven-
tion independent of BMD status in patients reaching a yearly 
cumulative dose of about 800 to 900 mg prednisolone.83 This 
equals 2 courses of prednisolone or a daily dose of 2.5 mg 
prednisolone for 1 year.
Anabolic drugs like the parathyroid hormone analogue 
teriparatide stimulate bone formation through effects on 
osteoblasts and osteocytes, and may therefore more directly 
target the main pathophysiological mechanism in CS induced 
osteoporosis. Teriparatide has been found to be superior to 
alendronate in CS-induced osteoporosis, both regarding change 
in BMD and morphometric vertebral fractures,178,179 but there 
is so far weak evidence for hip fracture reduction.171 In post-
menopausal women with osteoporosis, strontium ranelate 
also has been found to reduce fracture risk.180 The treatment 
has combined anabolic and anti-catabolic effect, in addition 
to effect on BMD due to incorporation of strontium into 
hydroxyapatite instead of calcium. This strengthens the corre-
lation between increase in BMD and reduction in fracture risk, 
compared to other osteoporosis therapies, and might thereby 
increase the value of follow-up BMD as a marker of therapeutic 
efficacy. However, studies of the effect of strontium ranelate 
in CS-induced osteoporosis have not been published.180
Table 3 recommendations for prevention and treatment of osteo-
porosis in COPD patients
• Avoid further bone loss
    Smoking cessation
   weight-bearing and strengthening exercise
   Adequate nutrition
    Maintain weight if not overweight
    rehabilitation programs in moderate to severe disease169
•  COPD – treatment
      Long-acting bronchodilators to all patients where airway 
obstruction might limit the level of physical activity170
      ICS or ICS/LABA or long-acting anticholinergics in severe COPD  
in order to reduce frequency of exacerbations
    reduce CS exposure by:
    Maintenance therapy: ICS in moderate doses
    exacerbations: Consider dependent on the individual patient:
  A.  Lower OCS dose (30 mg prednisolone for 7 to 8 days)
  B.  High-dose ICS/LABA after one dose of prednisolone 30 mg135
•  Calcium and vitamin D (1200 mg and 800 IU, respectively)172
   To everyone aged 50 years or more
    If start with OCS or high-dose ICS
•  Bisphosphonates
    If daily dose of CS  5 to 7.5 mg and T-score  –1 (–1.5)
    If yearly cumulative dose of CS  800 mg prednisolone
    If previous fragility fracture and T-score  –2.5 if no use of CS
•  estrogen
    Consider in hypogonadal premenopausal women exposed to CS
•  PTH analogues
    Consider in CS users with high risk of fractures
Abbreviations: CS, corticosteroids; ICS, inhaled corticosteroids; OCS, oral 
corticosteroids; LABA, long-acting β2-agonist.International Journal of COPD 2009:4 376
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Conclusions
Among available treatments for COPD, only CS-treatment 
has documented adverse effects of clinical significance. 
CS have both direct adverse effects on bone and indirect 
effects due to muscle weakening and atrophy. These effects 
are dose dependent both regarding daily dose, duration and 
cumulative dose. Less negative effects are seen by sporadic 
compared to continuous use, but lower continuous doses 
have less detrimental effects on bone than frequent high-
dose course of OCS. High doses of ICS seem to increase 
bone loss, but the extent of this effect is discussed because 
it is difficult to differentiate between the effect of ICS dose 
used, other risk factors, prior or concomitant use of OCS and 
not at least, disease severity. The health care should increase 
focus on healthy lifestyle and use of limited CS doses, as 
well as be aware of potential osteoporosis development in 
this group of patients. Studies on the effectiveness of use 
of long-acting anticholinergics or use of combinations with 
moderate ICS doses in severe COPD are warranted, as well 
as development of new anti-inflammatory drugs with specific 
effects on COPD inflammation and minor adverse effect 
on bone.
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